Monday, March 8, 2021

For Cellectar Biosciences Inc. [CLRB], ROTH Capital sees a rise to $10. What next?

Must read

A look IntoAtomera Incorporated (ATOM)

Atomera Incorporated (NASDAQ: ATOM) has announced the successful sale of one of its development projects.  ATOM stock was last closed at $25.27. Based on...

Cellectar Biosciences Inc. [NASDAQ: CLRB] closed the trading session at $1.24 on 06/09/20. The day’s price range saw the stock hit a low of $1.22, while the highest price level was $1.38. The stocks have a year to date performance of -44.89 percent and weekly performance of -6.06 percent. The stock has been moved at -35.08 percent over the last six months. The stock has performed -28.32 percent around the most recent 30 days and changed -38.31 percent over the most recent 3-months.

If compared to the average trading volume of 476.82K shares, CLRB reached to a volume of 2428295 in the most recent trading day, which is why market watchdogs consider the stock to be active.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .


Here’s what leading stock market gurus have to say about Cellectar Biosciences Inc. [CLRB]:

ROTH Capital have made an estimate for Cellectar Biosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 21, 2020. The new note on the price target was released on September 13, 2019, representing the official price target for Cellectar Biosciences Inc. stock. Previously, the target price had yet another raise to $2.70, while Ladenburg Thalmann analysts kept a Buy rating on CLRB stock.

The Average True Range (ATR) for Cellectar Biosciences Inc. is set at 0.15 The Price to Book ratio for the last quarter was 2.82, with the Price to Cash per share for the same quarter was set at 0.76.

CLRB stock trade performance evaluation

Cellectar Biosciences Inc. [CLRB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.06. With this latest performance, CLRB shares dropped by -28.32% in over the last four-week period, additionally sinking by -35.08% over the last 6 months – not to mention a drop of -44.39% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLRB stock in for the last two-week period is set at 44.40, with the RSI for the last a single of trading hit 43.92, and the three-weeks RSI is set at 43.72 for Cellectar Biosciences Inc. [CLRB]. The present Moving Average for the last 50 days of trading for this stock 1.4454, while it was recorded at 1.1460 for the last single week of trading, and 1.8828 for the last 200 days.

Cellectar Biosciences Inc. [CLRB]: An insightful look at the core fundamentals

Return on Total Capital for CLRB is now -124.10, given the latest momentum, and Return on Invested Capital for the company is -123.94. Return on Equity for this stock declined to -126.28, with Return on Assets sitting at -103.23. When it comes to the capital structure of this company, Cellectar Biosciences Inc. [CLRB] has a Total Debt to Total Equity ratio set at 5.82. Additionally, CLRB Total Debt to Total Capital is recorded at 5.50, with Total Debt to Total Assets ending up at 4.31. Long-Term Debt to Equity for the company is recorded at 5.33, with the Long-Term Debt to Total Capital now at 4.40.

Reflecting on the efficiency of the workforce at the company, Cellectar Biosciences Inc. [CLRB] managed to generate an average of -$1,761,614 per employee.Cellectar Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.60.

Earnings per share (EPS) analysis for Cellectar Biosciences Inc. [CLRB] stock

With the latest financial reports released by the company, Cellectar Biosciences Inc. posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.69/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLRB.

Cellectar Biosciences Inc. [CLRB]: Insider Ownership positions

There are presently around $2 million, or 30.80% of CLRB stock, in the hands of institutional investors. The top three institutional holders of CLRB stocks are: BOXER CAPITAL, LLC with ownership of 920,000, which is approximately 0% of the company’s market cap and around 1.60% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 232,102 shares of the stock with an approximate value of $0.27 million in CLRB stocks shares; and SPHERA FUNDS MANAGEMENT LTD., currently with $0.1 million in CLRB stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Cellectar Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 8 institutional holders increased their position in Cellectar Biosciences Inc. [NASDAQ:CLRB] by around 178,306 shares. Additionally, 4 investors decreased positions by around 9,009 shares, while 8 investors held positions by with 1,283,251 shares. The mentioned changes placed institutional holdings at 1,470,566 shares, according to the latest SEC report filing. CLRB stock had 7 new institutional investments in for a total of 145,206 shares, while 1 institutional investors sold positions of 6 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

More articles


Please enter your comment!
Please enter your name here

Latest article

A look IntoAtomera Incorporated (ATOM)

Atomera Incorporated (NASDAQ: ATOM) has announced the successful sale of one of its development projects.  ATOM stock was last closed at $25.27. Based on...

Armstrong Flooring Inc (AFI) Hitting the mark

Armstrong Flooring Inc (AFI) ‎stock got some oxygen when the company publicly announced to sell its production facility and real state property of theSouth...

The Goodyear Tire & Rubber Company (GT): Keeping an Eye On The Long Term

The Goodyear Tire & Rubber Company (NASDAQ: GT) has acquired rival Cooper Tire & Rubber Company (NYSE: CTB) for $2.8 billion. The takeover will...

OCUL stock: Ocular Therapeutix (OCUL) Is Better Than You Think

Ocular Therapeutix (OCUL) has performed well over the past year. OCUL has experienced a 248.76% gain in the last year, while its stock has...

Examining the Technicals of Levi Strauss & Co (NYSE: LEVI)

Levi Strauss & Co (NYSE: LEVI), one of the world's most famous denim brands, is recovering from the COVID-19 crisis. As a result of...

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.